|
1) Dember LM. Amyloidosis-associated kidney disease. J Am Soc Nephrol. 2006; 17: 3458-71
|
|
|
|
2) 石原得博. アミロイドーシスの分類. 腎と透析. 2007; 62: 149-53
|
|
|
|
|
3) Naiki H, Gejyo F. Kinetic analysis of amyloid fibril formation. Methods Enzymol. 1999; 309: 305-18
|
|
|
|
|
|
4) Yamamoto S, Hasegawa K, Yamaguchi I, et al. Low concentration of sodium dodecyl sulfate induce the extension of beta 2-microglobulin-related amyloid fibrils at a neutral pH. Biochemistry. 2004; 43: 11075-82
|
|
|
|
|
|
5) Ohashi K, Hara M, Kawai R, et al. Cervical discs are most susceptible to beta2-microglobulin amyloid deposition in the vertebral column. Kidney Int. 1992; 41: 1646-52
|
|
|
|
|
|
6) Jadoul M, Garbar C, Noel H, et al. Histological prevalence of beta2-microglobulin amyloidosis in hemodialysis: a prospective post-morten study. Kidney Int. 1997; 51: 1928-32
|
|
|
|
|
|
7) 下条文武. 透析アミロイドーシス: 発症機序解明と治療戦略. 日本内科学会雑誌. 2005; 94: 56-60
|
|
|
|
|
|
8) Miyata T, Jadoul M, Kurokawa K, et al. β2 microglobulin in renal disease. J Am Soc Nephrol. 1998; 9: 1723-35
|
|
|
|
|
|
9) 乳原善文, 香取秀幸, 曽川陽子, 他. 腎アミロイドーシスの診断と治療. 腎と透析. 2007; 62: 231-41
|
|
|
|
|
|
10) Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study. Ann Intern Med. 2004; 140: 85-93
|
|
|
|
|
|
11) Gono T, Matsuda M, Dohi N, et al. Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation. Internal Medicine. 2003; 42: 72-7
|
|
|
|
|
|
12) 松田正之. ALアミロイドーシスの治療と展望. 腎と透析. 2007; 62: 188-93
|
|
|
|
|
|
13) 高市憲明, 香取秀幸, 星野純一. 自己末梢血幹細胞移植併用メルファラン大量療法を行った原発性ALアミロイドーシス4例の成績. 厚生労働科学研究費補助金 難治性疾患克服研究事業 アミロイドーシスに関する調査研究 平成18年度 総括・分担研究報告書. 2007. p. 29-31
|
|
|
|
|
|
14) 島崎千尋, 麻奥英毅, 阿倍正博, 他. 原発性ALアミロイドーシスに対する中等量メルファランによる寛解導入療法と自家末梢血幹細胞移植療法: 臨床試験の進捗状況. 厚生労働科学研究費補助金 難治性疾患克服研究事業 アミロイドーシスに関する調査研究 平成18年度 総括・分担研究報告書. 2007. p. 22-5
|
|
|
|
|
|
15) BJH guidline. Guidelines on the diagnosis and management of AL amyloidosis. 2004 United Kingdom Myeloma Forum. Br J Haematol. 2004; 125: 681-700
|
|
|
|
|
|
16) Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004; 103: 2936-8
|
|
|
|
|
|
17) 吉崎和幸, 萩原圭祐, 西川哲平, 他. AA アミロイドーシスの治療と展望. 腎と透析. 2007; 62: 199-207
|
|
|
|
|
|
18) Gottenberg J, Florence V, Fabrice B, et al. Anti-tumor necrosis factor α therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides?a follow up report of tolerability and efficacy?. Arthritis Rheum. 2003; 48: 2019-24
|
|
|
|
|
|
19) Okuda Y, Takasugi K. Successful use of human-ized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum. 2006; 54: 2997-3000
|
|
|
|
|
|
20) Dember LM, Hawkins PN, Hazenberg BPC, et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med. 2007; 356: 2349-60
|
|
|
|
|
|
21) Gejyo F, Yamada T, Odani S, et al. A new form of amyloid protein associated with chronic hemodialysis was identified as β2-microglobulin. Biochem Biophys Res Commun. 1985; 129: 701-6
|
|
|
|
|
|
22) 山本 卓, 下条文武. 透析アミロイドーシスの内科的治療と展望. 腎と透析. 2007; 62: 217-20
|
|
|
|
|
|
23) Jaccard A, Moreau P, Leblond V, et al. Higy-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007; 357: 1083-93
|
|
|
|
|